639863-77-7

Basic information

• Product Name: 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(piperidin-4-yl)urea
• Synonyms: 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(piperidin-4-yl)urea
• CAS NO: 639863-77-7
• Molecular Weight: 413.535
• Mol File: 639863-77-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(piperidin-4-yl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(piperidin-4-yl)urea(639863-77-7)
• EPA Substance Registry System: 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(piperidin-4-yl)urea(639863-77-7)

Safety Data

• Hazardous Substances Data: 639863-77-7(Hazardous Substances Data)

Usage

Description

1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(piperidin-4-yl)urea is a complex organic compound characterized by its urea group attached to a piperidine ring and two benzyl groups. The presence of a fluorine atom and an isobutoxy group in its structure suggests potential pharmacological or biological properties, making it a compound of interest for further research and development in medicinal chemistry.

Uses

Used in Pharmaceutical Industry:
1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(piperidin-4-yl)urea is used as a potential pharmaceutical candidate for [application reason] due to its complex structure and the presence of functional groups that may exhibit pharmacological or biological activities.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(piperidin-4-yl)urea is used as a subject for further research and development. Its unique structural features, including the urea group, piperidine ring, benzyl groups, fluorine atom, and isobutoxy group, make it a promising compound for exploring new therapeutic applications and understanding its interactions with biological targets.

Upstream product

• 639863-76-6 N-(4-fluorobenzyl)-N-[1-(trifluoroacetyl)piperidin-4-yl]-N'-(4-isobutyloxybenzyl)carbamide 
• 140-75-0 para-fluorobenzylamine 
• 41979-39-9 4-piperidone hydrochloride 
• 13362-94-2 2-[4-(2-methylpropoxy)phenyl]acetic acid 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 65220-86-2 1-(trifluoroacetyl)-4-piperidone 
• 639863-74-4 N-(4-fluorobenzyl)-1-(trifluoroacetyl)piperidin-4-amine 
• 639863-75-5 1-(isocyanatomethyl)-4-(2-methylpropoxy)benzene 
• 459-57-4 4-fluorobenzaldehyde 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 4734-09-2 1-[4-(2-methylpropyloxy)phenyl]methanamine 
• 767-00-0 4-cyanophenol 
• 5203-15-6 4-(2-methylpropoxy)benzonitrile 

Downstream Products

• 639861-37-3 N-{1-[2-(1,3-dioxolan-2-yl)ethyl]piperidin-4-yl}-N-(4-fluorobenzyl)-N'-(4-isobutoxybenzyl)carbamide hydrochloride 

Relevant articles and documents

11C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand

Pimavanserin is a selective serotonin 2A receptor (5-HT2AR) inverse agonist that has shown promise for treatment of psychotic symptoms in patients with Parkinson's disease. Here, we detail the 11C-labeling and subsequently evaluate pimavanserin as a PET-radioligand in pigs. [11C]Pimavanserin was obtained by N-methylation of an appropriate precursor using [11C]MeOTf in acetone at 60 °C giving radiochemical yields in the range of 1-1.7 GBq (n = 4). In Danish Landrace pigs the radio ligand readily entered the brain and displayed binding in the cortex in accordance with the distribution of 5-HT2ARs. However, this binding could not be blocked by either ketanserin or pimavanserin itself, indicating high nonspecific binding. The lack of displacement by the 5-HT2R antagonist and binding in the thalamus suggests that [11C]pimavanserin is not selective for the 5-HT2AR in pigs.

N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECPTOR AGENTS

Disclosed herein are compounds of Formula I, or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Disclosed are also methods of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Furthermore, methods of treating psychotic disease using a compound of Formula I are disclosed.